• Positive findings from XanaCIDD phase 2a trial in major depressive disorder
• Accelerating recruitment for XanaMIA phase 2b/3 Alzheimer's disease trial
• Received $9.0 million R&D tax incentive rebate

Actinogen Medical has released its interim financial results for the six months ended 31 December 2024, showcasing strong business momentum. Key highlights include accelerating recruitment for the XanaMIA phase 2b/3 Alzheimer's disease trial, positive findings from the completed XanaCIDD phase 2a major depressive disorder trial, and the World Health Organization granting a new and unique International Nonproprietary Name 'emestedastat' to Xanamem. The company has also commenced production of a scale-up batch of drug substance, received a $9.0 million R&D tax incentive rebate, and is preparing for commercialization across various aspects of the business. The XanaCIDD trial results validated Xanamem's mechanism of action in controlling brain cortisol, which is driving the accelerated recruitment in the XanaMIA Alzheimer's trial. Actinogen is confident in a positive outcome from the XanaMIA trial, with interim results expected in Q4 2025 and final results in H2 2026. The company remains committed to proactive management of all aspects of the business, including optimizing current trials, planning for marketing approvals, and preparing for commercialization, while balancing partnering efforts and building shareholder returns.

Actinogen is firmly confident that Xanamem has the potential to be a first-in-class drug for the treatment of Alzheimer's disease and a first-in-class antidepressant with a novel mechanism. The company is committed to proactive management of all aspects of the business to ensure the best possible outcomes for patients and shareholders, including optimizing current clinical trials, forward planning for marketing approvals, and preparing for commercialization.